The clinical application of camrelizumab on advanced hepatocellular carcinoma.

Camrelizumab (also known as SHR-1210), a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells....